Literature DB >> 1516251

The spleen? Who needs it anyway?

M Hazlewood, D S Kumararatne.   

Abstract

Mesh：

Year:  1992        PMID： 1516251      PMCID： PMC1554457          DOI： 10.1111/j.1365-2249.1992.tb06956.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  33 in total

1.  Alterations of the immune system following splenectomy in childhood.

Authors:  E Kreuzfelder; U Obertacke; J Erhard; R Funk; R Steinen; N Scheiermann; O Thraenhart; F W Eigler; K P Schmit-Neuerburg
Journal:  J Trauma       Date:  1991-03

Review 2.  The evolution of B-cell clones.

Authors:  I C MacLennan; Y J Liu; S Oldfield; J Zhang; P J Lane
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

3.  The spleen in lymphocyte migration.

Authors:  R Pabst
Journal:  Immunol Today       Date:  1988-02

4.  Infections after splenectomy.

Authors:  M Constantoulakis; P Economopoulos; A Constantopoulos
Journal:  Ann Intern Med       Date:  1973-05       Impact factor: 25.391

5.  Selective depression of thymus-independent anti-DNP antibody responses induced by adult but not neonatal splenectomy.

Authors:  D Gray; D Chassoux; I C MacLennan; H Bazin
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

6.  Marginal zone macrophages and their role in the immune response against T-independent type 2 antigens: modulation of the cells with specific antibody.

Authors:  G Kraal; H Ter Hart; C Meelhuizen; G Venneker; E Claassen
Journal:  Eur J Immunol       Date:  1989-04       Impact factor: 5.532

7.  Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response.

Authors:  W Timens; A Boes; T Rozeboom-Uiterwijk; S Poppema
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

8.  Immune status and response to immunization with polysaccharide vaccines of a healthy, congenitally asplenic woman.

Authors:  P J McElroy; F I Henderson; D L Brown
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

9.  Splenic salvage vs splenectomy. Care of the trauma patient.

Authors:  V A Hansen; M B Johnson; W D Rappaport
Journal:  AORN J       Date:  1991-06       Impact factor: 0.676

10.  Impaired antipneumococcal antibody production in patients without spleens.

Authors:  F Di Padova; M Dürig; F Harder; C Di Padova; C Zanussi
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05
View more
  6 in total

Review 1.  Regeneration of autotransplanted splenic fragments: basic immunological and clinical relevance.

Authors:  R Pabst
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

2.  Long term management after splenectomy. Monitor antibody levels after vaccination.

Authors:  S Obaro; D C Henderson; M Monteil
Journal:  BMJ       Date:  1994-01-29

3.  Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed.

Authors:  D J Waghorn
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

4.  Management of patients undergoing splenectomy in an Irish teaching hospital: impact of guidelines.

Authors:  J O'Donnell; G McGreal; P Daly; R Crowley; M C Barry; P Broe; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2004 Jul-Sep       Impact factor: 1.568

5.  Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients.

Authors:  G K Wong; S Goldacker; C Winterhalter; B Grimbacher; H Chapel; M Lucas; D Alecsandru; D McEwen; I Quinti; H Martini; C Milito; R E Schmidt; D Ernst; T Espanol; A Vidaller; J Carbone; E Fernandez-Cruz; V Lougaris; A Plebani; N Kutukculer; L I Gonzalez-Granado; R Contreras; S Kiani-Alikhan; M A A Ibrahim; J Litzman; A Jones; H B Gaspar; L Hammarstrom; U Baumann; K Warnatz; A P Huissoon
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Critical mass of splenic autotransplant needed for the development of phagocytic activity in rats.

Authors:  R G Marques; C E R Caetano; C F Diestel; E Lima; M C Portela; A V Oliveira; M B N Oliveira; M Bernardo-Filho
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.